若生智能
Drug Database
EP

epidermal growth factor receptor (EGFR pharmDx / EGFR pharmDx Kit)

✓ Approved

Dako · EGFR · 辅助诊断

什么是 epidermal growth factor receptor？

epidermal growth factor receptor 是一种辅助诊断，由Dako研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

商品名EGFR pharmDx, EGFR pharmDx Kit
公司Dako
药物类别辅助诊断
分子靶点EGFR
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Dako

作用机制

分子靶点

epidermal growth factor receptor 作用于 1 个分子靶点：

EGFRepidermal growth factor receptor (ERBB1, NNCIS)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

epidermal growth factor receptor 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedThe Journal of the Association of Physicians of India2026-08-03

Synchronous Uterine Leiomyosarcoma and Pulmonary Adenocarcinoma: A Rare Oncological Puzzle.

Arpan, Kaur Avneet A, Dutta Archana A, Singh Navrajbir N

The occurrence of dual primary malignancies is an uncommon clinical phenomenon. This case report details a 65-year-old female presenting with both uterine leiomyosarcoma (LMS) and pulmonary adenocarcinoma, initially misdiagnosed as a metastatic spindle cell tumor. The patient presented with foul-smelling vaginal discharge, irregular menses, lower limb swelling, and a nonproductive cough. Imaging and biopsies revealed a necrotic uterine mass diagnosed as LMS and a left upper lobe lung mass identified as adenocarcinoma. Genetic testing of the lung tumor showed an epidermal growth factor receptor (EGFR) exon 19 deletion mutation. Treatment included chemotherapy targeting both malignancies, surgical resection of the uterine tumor, and targeted therapy for the lung adenocarcinoma. This case underscores the importance of thorough diagnostic evaluation in patients with multiple tumors to distinguish between metastatic disease and dual primary malignancies, as treatment strategies differ significantly.

PMID 42543964
阅读全文 →
PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-03

[Long-term remission with venetoclax plus azacitidine in acute myeloid leukemia with negative conversion of FLT3 companion diagnostic testing at relapse].

Yoshihara Satsuki S, Toya Takashi T, Handa Tomoyuki T, Ogawa Seishi S et al.

An 80-year-old man was diagnosed with acute myeloid leukemia (AML), and molecular analysis identified FLT3-ITD, TKD mutations. Induction chemotherapy with daunorubicin plus cytarabine achieved hematological complete remission; however, extramedullary infiltration was detected in the skin and central nervous system. Due to this extramedullary disease, treatment with mitoxantrone plus high-dose cytarabine was administered, leading to systemic complete remission. Two cycles of the same regimen were then added. The patient relapsed 5 months later, at which time FLT3 mutations were no longer detectable by a companion diagnostic test. However, targeted sequencing analysis identified a novel FLT3-ITD positive minor clone. Treatment with venetoclax plus azacitidine was then started. The patient achieved complete remission and has remained relapse-free for more than 2 years. In this case, the FLT3 mutation companion diagnostic test result became spontaneously negative without FLT3-directed treatment, and the response to venetoclax plus azacitidine was favorable. This case highlights the importance of molecular testing not only at diagnosis but also at relapse for appropriate treatment selection.

PMID 42543635
阅读全文 →
PubMedYakugaku zasshi : Journal of the Pharmaceutical Society of Japan2026-08-03

[Pharmaceutical Verification of Chemotherapy-induced Adverse Events].

Saito Yoshitaka Y

Managing adverse events is important for optimizing cancer treatment and ensuring high patient satisfaction. Studies have assessed (1) anti-epidermal growth factor receptor (EGFR) monoclonal antibody-induced skin toxicities, (2) development of severe neutropenia by renally excreted anticancer drugs in patients with renal impairment (RI), and (3) pharmaceutical care in the treatment of immune checkpoint inhibitors (ICIs). We identified liver metastasis as a risk factor and preemptive systemic antibiotic administration with anti-inflammatory effect as a preventive factor for grade ≥2 overall skin toxicities in anti-EGFR treatment for metastatic colorectal cancer (mCRC). Additional prophylactic topical steroids to systemic minocycline significantly prevented grade ≥2 rashes, but did not mitigate overall skin toxicities. Patients receiving trifluridine/tipiracil (FTD/TPI)-based chemotherapy for mCRC were assessed, resulting in significantly higher early severe neutropenia development among patients with RI. Additionally, we assessed the impact of RI on severe neutropenia development in carboplatin+pemetrexed-based chemotherapy for thoracic cancer. Consequently, severe neutropenia in the first cycle and all-treatment cycles was significantly more confirmed in patients with RI. We assessed the usefulness of pharmaceutical interventions in ICI treatment, which suggested that pharmaceutical care may improve quality of outpatient ICI treatment, and pharmaceutical intervention during the first three months after initiation of ICI treatment is crucial. Our studies have found clinically important outcomes that support the provision of less onerous chemotherapy.

PMID 42543606
阅读全文 →
PubMedDoklady. Biochemistry and biophysics2026-08-03

Insulin-Like Growth Factor 2 Modulates Macrophage Polarization: the Role of the IGF2-IGFBP6 Axis.

Averinskaya D A DA, Shkurnikov M Yu MY

Triple-negative breast cancer (TNBC) is characterized by an aggressive clinical course and extremely limited targeted therapy options. One of the key drivers of immunosuppression in the tumor microenvironment is the polarization of tumor-associated macrophages (TAMs) towards the M2 phenotype. In the present study, we investigated the effect of insulin-like growth factor 2 (IGF2)-the primary ligand of the IGF1R receptor and a target of the inhibitory protein IGFBP6-on the transcriptional profile of macrophages polarized in vitro from the THP-1 cell line. We demonstrate that IGF2 exerts fundamentally different effects depending on the baseline functional state of the macrophages: in immature (M0) and M2-polarized cells, it induces the expression of pro-inflammatory genes, whereas in M1 macrophages it triggers pronounced immunosuppressive reprogramming. These findings suggest that IGFBP6, by inhibiting IGF2, may sustain an anti-tumor immune response within the TNBC microenvironment.

PMID 42545576
阅读全文 →
PubMedCureus2026-08-03

Pulmonary Hypertension in a 19-Year-Old Patient Due to a Mutation in the Bone Morphogenetic Protein Receptor Gene: A Case Report.

Pelloni Federico F, De Perna Maria Luisa ML, Moschovitis Giorgio G

Pulmonary hypertension (PH) is a chronic disease with a high socio-economic and health burden, often misdiagnosed or diagnosed late due to the absence of specific symptoms, with often fatal outcomes. Despite numerous studies on the disorder, the exact mechanisms of onset are not yet fully understood, and the therapeutic possibilities, although increasing, are still few and not curative. We report the case of an apparently healthy 19-year-old woman who presented with recurrent syncope, dyspnea, and chest pain on exertion. Diagnostic work-up showed severe PH, and genetic analysis revealed a truncating mutation in the bone morphogenetic protein receptor gene 2 as an etiologic factor. Similar mutations in the same gene, inherited in an autosomal-dominant pattern, are already known as the causative factor of PH. Despite the implementation of guideline-directed medical therapy, the clinical situation rapidly deteriorated, and the patient died due to a pulmonary hemorrhage. This case report highlights the importance of early diagnosis, especially at a young age, and the need for treatment by a center specialized in these disorders.

PMID 42544166
阅读全文 →
PubMedThe American journal of case reports2026-08-03

Pustules in Stevens-Johnson Syndrome.

Nagata Shunya S, Kuki Takaie T, Kato Miyuki M

BACKGROUND Stevens-Johnson syndrome (SJS) is characterized by widespread, epidermal necrosis and mucosal involvement mediated by a delayed-type hypersensitivity reaction. Although rapidly progressive epidermal detachment is known to result in blister formation, pustular lesions are rare in SJS. CASE REPORT A 25-year-old male patient with no significant medical history or regular medication presented to the emergency department with a fever and rash. The fever had developed 7 days before the current presentation and was followed 4 days later by lip swelling, conjunctival hyperemia, and sore throat, which caused difficulty with oral intake. Two days before presentation, a generalized rash and dysuria developed, prompting evaluation at our hospital. A clinical examination found multiple, 3-mm pustules surrounding erythema on the face, chest, and back. Scattered erosions were observed on less than 10% of body surface, including the distal extremities, lips, buccal mucosa, and genital area. The conjunctivae displayed marked pseudomembrane formation. Histopathological analysis found that the erosions contained necrotic keratinocytes in the epidermis, with mild vacuolar changes at the dermo-epidermal junction, while the pustules contained serous exudate with scattered neutrophils. Based on these findings, SJS was diagnosed. A drug-induced lymphocyte stimulation test was positive for loxoprofen. The patient responded well to prednisolone therapy. CONCLUSIONS Although no drug exposure or infection preceding the symptoms was identified at admission, SJS was diagnosed by exclusion on the basis of the clinical manifestations and diagnostic criteria. A drug-induced lymphocyte stimulation test may help identify the causative drug. Neutrophilic infiltration into blisters formed by progressive, epidermal necrosis may occasionally result in pustule-like eruptions in SJS.

PMID 42543736
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多epidermal growth factor receptor